MIW815
Total Payments
$3.8M
Transactions
49
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $520,184 | 12 | 0 |
| 2019 | $978,623 | 16 | 2 |
| 2018 | $1.6M | 12 | 0 |
| 2017 | $725,415 | 9 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.8M | 49 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE IB OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MIW815 ADU S100 ADMINISTERED BY INTRATUMORAL INJECTION WITH PDR001 TO PATIENTS WITH ADVANCED METASTATIC SOLID TUMORS OR LYMPHOMAS | Novartis Pharmaceuticals Corporation | $2.0M | 0 |
| A PHASE I OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MIW815 ADU S100 ADMINISTERED BY INTRATUMORAL INJECTION TO PATIENTS WITH ADVANCED METASTATIC SOLID TUMORS OR LYMPHOMAS | Novartis Pharmaceuticals Corporation | $1.6M | 0 |
| A PHASE I OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MIW815 ADU S100 ADMINISTERED BY INTRATUMORAL INJECTION TO PATIENTS WITH ADVANCED METASTATIC SOLID TUMORS OR LYMPHOMAS | NOVARTIS PHARMACEUTICALS CORPORATION | $114,642 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $981.75 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.8M
- Total Doctors 2
- Transactions 49
About MIW815
MIW815 is a drug associated with $3.8M in payments to 2 healthcare providers, recorded across 49 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $520,184 was paid across 12 transactions to 0 doctors.
The most common payment nature for MIW815 is "Unspecified" ($3.8M, 100.0% of total).
MIW815 is associated with 4 research studies, including "A PHASE IB OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MIW815 ADU S100 ADMINISTERED BY INTRATUMORAL INJECTION WITH PDR001 TO PATIENTS WITH ADVANCED METASTATIC SOLID TUMORS OR LYMPHOMAS" ($2.0M).